MA
GNCA

MYDA Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

MYDA Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,188
Closed -$39K – 212
2017
Q4 		$39K Buy
+4,188
New +$42.1K 0.02% 150

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MYDA Advisors's GNCA Position: Q1 2018 in Review

MYDA Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2018, closing a stake of 4,188 shares — an estimated $39K sold.

MYDA Advisors first reported a position in GNCA in Q4 2017 and held it in 1 quarter. The position peaked at $39K in Q4 2017. 65 funds tracked by Wall St. Rank hold GNCA as of Q1 2018.

  • MYDA Advisors reported no remaining Genocea Biosciences, Inc. position as of Q1 2018 after selling out during the quarter.
  • MYDA Advisors sold 4,188 Genocea Biosciences, Inc. shares in Q1 2018, an estimated $39K.
  • MYDA Advisors first reported a position in Genocea Biosciences, Inc. in Q4 2017 and held it in 1 quarter.
  • MYDA Advisors's Genocea Biosciences, Inc. position peaked at $39K in Q4 2017.
  • 65 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2018.

Based on MYDA Advisors's 13F filing for Q1 2018, filed 10 May 2018.